Evidence map›Paper›PMID 35028858›Full record

ArticleMolecular biology reports2022

Notch pathway inhibition mediated by arsenic trioxide depletes tumor initiating cells in small cell lung cancer.

Meng-Hang Yang, Bing Li, Ke-Jie Chang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. [Research Progress on the Role of Notch Signaling Pathway in Small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Meng-Hang YangDepartment of Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Bing LiDepartment of Respiratory and Critical Care Medicine, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China. libing1962@smmu.edu.cn.
Ke-Jie ChangDepartment of Thoracic Oncology, Cancer Center of the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, Guangdong, China. changkj@mail.sysu.edu.cn.
Fifth Affiliated Hospital of Sun Yat-sen University · CNShanghai Pulmonary Hospital · CNTongji University · CN

Funding

National Natural Science Foundation of China 81602618National Natural Science Foundation of China 81672929National Natural Science Foundation of China 82074065
6 · The paper itself

Abstract

backgroundSmall cell lung cancer (SCLC) is the most malignant type of lung cancer. We previously reported that arsenic trioxide (As METHODS AND

resultsTICs were enriched by culturing human SCLC cell line as sphere cells in specified serum-free medium. The expression of stem cell markers, CD133 and CD44, and the in vivo tumorigenicity of both TICs and their parental cells were examined. To demonstrate the inhibitory effect of As

conclusionsOur data demonstrate that As

Indexed as

Antineoplastic AgentsArsenicalsLung NeoplasmsSmall Cell Lung CarcinomaAnimalsApoptosisArsenic TrioxideCell Line, TumorHumansMiceMice, NudeNeoplastic Stem CellsAntineoplastic AgentsArsenicalsArsenic TrioxideArsenic trioxideNotchSmall cell lung cancerTumor initiating cells

Identifiers

PMID35028858
OpenAlexW4206729255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.